Does OKT3 increase the risk of recurrent hepatitis B in patients transplanted for hepatitis B?

✍ Scribed by Chi-Jen Chu; Anna S.F. Lok

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 176 KB
• Volume: 6
• Category: Article
• ISSN: 1527-6465
• DOI: 10.1002/lt.500060623

✦ Synopsis

The aim of this work was to analyze whether the treatment of acute rejection of orthotopic liver transplants (OLT), either with corticoids or OKT3, has any effect on levels of hepatitis B virus (HBV)-DNA and HbsAg in individuals which were originally affected by cirrhosis or fulminant hepatic failure as a result of B virus. We have found that HBV-DNA is present in macrophages, B cells and both CD4؉ and CD8؉ T cells after OLT in all cases studied. Interestingly, the levels of HBV-DNA and HbsAg in the serum analyzed were increased extremely rapidly in the patients treated with OKT3 in an acute rejection episode. However, the serum levels of HBV-DNA and HbsAg found were lower when the patients were treated with steroids, and were not found in non-treated patients. As the serum levels of HBV-DNA increase, the process of liver reinfection could be accelerated; therefore, these results may help to understand how OKT3 and corticoids immunosuppressive therapy may accelerate the reinfection of OLT by HBV. In conclusion, our results suggest that special care must be taken in the use of OKT3 in the treatment of acute liver rejection episodes in chronic or fulminant HBV transplanted patients.